Cited by 295Antifungal resistance and susceptibilityNeutropenia and Cancer InfectionsFungal Infections and Studies

Predictors of Adverse Outcome in Cancer Patients with Candidemia

Anaissie, Elias J, Rex, John H, Uzun, Ömrün, Vartivarian, Shahe·1998·The American Journal of Medicine

Abstract

Background Many factors, including severity of illness, neutropenia, intravenous catheter management, and drug therapy may affect the outcome of candidemia in cancer patients.Methods The records of all patients at M. D. Anderson Cancer Center who developed one or more positive blood cultures for Candida spp between January 1, 1988, and December 31, 1992, were retrospectively reviewed. Four hundred ninety-one episodes of candidemia were identified, for which 476 had complete medical records, which were reviewed in detail.Results By 3-month follow-up, 52% of the patients had died. Neutropenia, higher APACHE III score, and visceral dissemination were associated with poor prognosis. Cure rates, adjusted for severity of illness, were similar for fluconazole and amphotericin B treatment. Exchange of central venous catheters was associated with a modest improvement in prognosis.Conclusion Several factors that influence the outcome of candidemia in cancer patients have been identified. These factors may be relevant for the clinical management of cancer patients with candidemia, and for the design of therapeutic trials.

Integrity signals

Registry

Crossref · 10.1016/s0002-9343(98)00030-8

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Two large randomized studies and 2 large observational studies have demonstrated that fluconazole (400 mg/day) and amphotericin B deoxycholate (0.5-0.6 mg/kg per day) are similarly effective as therapy.

    “Two large randomized studies [105, 106] and 2 large observational studies [107, 108] have demonstrated that fluconazole (400 mg/day) and amphotericin B deoxycholate (0.5-0.6 mg/kg per day) are similarly effective as therapy.”

    From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [107]

  • Fungemia due to C. parapsilosis is very frequently associated with use of catheters.

    “An exception is made for fungemia due to C. parapsilosis, which is very frequently associated with use of catheters (A-II) [107].”

    From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [107]

  • In neutropenic patients, the gut is a source for disseminated candidiasis, evident from autopsy studies.

    “In neutropenic patients, the role of the gut as a source for disseminated candidiasis is evident from autopsy studies”

    From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [107]

  • In an individual patient, it is difficult to determine the relative contributions of the gut and a catheter as primary sources of fungemia.

    “in an individual patient, it is difficult to determine the relative contributions of the gut and a catheter as primary sources of fungemia [107,108,118].”

    From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [107]

Cites

Flagged first, then by citations

1 of the 36 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Anaissie, E. J., Rex, J. H., Uzun, Ö., & Vartivarian, S.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • The University of Texas Health Science Center at Houston (US)
Corresponding author
Anaissie, Elias J
Venue
The American Journal of Medicine
Publisher
Elsevier BV
Published
1998-03
Volume
104
Issue
3
Pages
238-245
ISSN
0002-9343 (ISSN-L)
OpenAlex
W2083121860
Cited by
295
References
36
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 5 · 2018: 4 · 2017: 8 · 2016: 1 · 2015: 9 · 2014: 6 · 2013: 9 · 2012: 11
FWCI
11.04
Type
journal article
Language
en
Open access
closed
Locations
  • The American Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer Pharmaceuticals
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Keywords
candidemia, candidiasis, cancer patients, prognosis, neutropenia, APACHE III score, visceral dissemination, fluconazole, amphotericin B, mortality, bloodstream infection
MeSH terms
Adult, Aged, Analysis of Variance, Antifungal Agents, Candidiasis, Female, Humans, Male, Middle Aged, Neoplasms, Predictive Value of Tests, Prognosis, Retrospective Studies, Risk, Risk Factors, Time Factors, Odds Ratio, Fungemia, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review